IMPEDIMED TECHNOLOGY BACKED BY NEW STUDY

Written on the 14 September 2016 by James Perkins

IMPEDIMED TECHNOLOGY BACKED BY NEW STUDY A STUDY has found that Brisbane-based company ImpediMed's (ASX: IPD) L-Dex technology (pictured) is effective in monitoring patients that are at-risk of breast cancer related lymphoedema.

The study, conducted in the United States and published in the journal Frontiers in Oncology, reported that 326 patients were monitored with the L-Dex technology  post axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB).

Through monitoring fluid status and body composition through bioimpedance spectroscopy, L-Dex allowed for early intervention for patients who showed further incidence of sub-clinical lymphoedema after undergoing either an ALND or SLNB and allowed reduction in the persistence of this condition by 99.5 per cent for ALND patients and 91.4 per cent for SLNB patients.

The study concluded, "The results of this retrospective study demonstrate that L-Dex assessments can be incorporated into routine breast cancer programs as part of follow-up."

The researchers, from Texas, noted that this was critically important, given new health guidelines in the US for monitoring the post-treatment follow-up care of for breast cancer patients.

"As we await the results of the post-approval L-Dex study currently underway, we are pleased at the publication of these important and positive clinical data for L-Dex," says Richard Carreon, ImpediMed Managing Director and CEO in a statement to the ASX today.

L-Dex was developed by Associate Professor Leigh Ward from the University of Queensland.

IPD is trading up 6.55 per cent on the ASX this morning, at $3.94 per share.



Author: James Perkins Connect via: Twitter LinkedIn

Latest News

1700 BRISBANE APARTMENTS NOW MANAGED BY FORTUNE 500 COMPANY JLL

MULTINATIONAL and Fortune 500 company JLL (NYSE: JLL) has expanded its Australian dominance in the property managemen...

HARVEY NORMAN HITS OUT AT 'FALSE NEWS' OF ASIC INVESTIGATION

RETAIL giant Harvey Norman (ASX: HVN) has vehemently rejected reports its accounts are under investigation by ASIC, s...

RARE GOOD NEWS FOR SLATER AND GORDON AS ASIC CLOSES INVESTIGATION

ASIC has cleared Slater and Gordon of deliberately falsifying its accounts after a three-month investigation.

It s...

Q & A WITH FACEBOOK GURU ANDY MCKEON AS HE JOINS AUSTRALIAN SOFTWARE COMPANY LIVETILES

HE was creative director at Apple under the legendary Steve Jobs, and is now a senior Facebook executive. In his n...

Related News

RAY OF HOPE FOR SLATER AND GORDON AS LENDERS STEP IN

EMBATTLED law firm Slater and Gordon (ASX: SGH) has announced to the ASX that it has launched confidential discussion...

SPROUTX PROVIDES THE SEED FOR AGTECH STARTUPS

AGTECH innovation fund SproutX has opened applications for its first accelerator round, backed by $10 million from...

GAS PRICES MAY FORCE BRICKWORKS TO TAKE MANUFACTURING OVERSEAS

BRICKWORKS Limited (ASX:BKW) chairman Robert Millner says soaring energy prices may force the company to turn to offs...

CHINA CONTINUES TO COLLECT AUSSIE PROPERTY ASSETS

CHINESE coin continues to dominate Australia's offshore real estate investment market, accounting for almost h...

EVENTS COMING UP

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter